Nitric oxide maintains endothelial redox homeostasis through PKM2 inhibition.
Mauro SiragusaJanina ThöleSofia-Iris BibliBert LuckAnnemarieke E LootKevin de SilvaIlka WittigJuliana HeidlerHeike StinglVoahanginirina RandriamboavonjyKarin KohlstedtBernhard BrüneAndreas WeigertBeate FisslthalerIngrid FlemingPublished in: The EMBO journal (2019)
Decreased nitric oxide (NO) bioavailability and oxidative stress are hallmarks of endothelial dysfunction and cardiovascular diseases. Although numerous proteins are S-nitrosated, whether and how changes in protein S-nitrosation influence endothelial function under pathophysiological conditions remains unknown. We report that active endothelial NO synthase (eNOS) interacts with and S-nitrosates pyruvate kinase M2 (PKM2), which reduces PKM2 activity. PKM2 inhibition increases substrate flux through the pentose phosphate pathway to generate reducing equivalents (NADPH and GSH) and protect against oxidative stress. In mice, the Tyr656 to Phe mutation renders eNOS insensitive to inactivation by oxidative stress and prevents the decrease in PKM2 S-nitrosation and reducing equivalents, thereby delaying cardiovascular disease development. These findings highlight a novel mechanism linking NO bioavailability to antioxidant responses in endothelial cells through S-nitrosation and inhibition of PKM2.
Keyphrases
- oxidative stress
- endothelial cells
- nitric oxide
- cardiovascular disease
- nitric oxide synthase
- dna damage
- ischemia reperfusion injury
- diabetic rats
- induced apoptosis
- type diabetes
- pi k akt
- vascular endothelial growth factor
- cell proliferation
- cardiovascular risk factors
- metabolic syndrome
- signaling pathway
- binding protein
- coronary artery disease
- reactive oxygen species
- cardiovascular events